NCT01279096已完成1 期
A Phase I Dose Escalation Study of Clofarabine Given in Combination With Multi-agent Therapy for Remission Induction in Pediatric Patients With Acute Lymphoblastic Leukemia in First Relapse or Refractory to First Line Therapy -
University Hospital, Lille4 个研究点 分布在 1 个国家目标入组 20 人开始时间: 2010年1月1日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 20
- 试验地点
- 4
- 主要终点
- maximum tolerated dose of clofarabine in combination with etoposide, asparaginase, mitoxantrone and dexamethasone
研究概览
简要总结
The purpose of this study is to determine Maximum Tolerated Dosage (MTD), Dosage Limited Toxicities (DLT), and the Rate Phase 2 Dosage of clofarabine when used in combination with etoposide, asparaginase, mitoxantrone and dexamethasone and to assess the feasibility and safety of this combination regimen to treat children with high risk relapsed or refractory acute lymphoblastic leukemia (ALL).
详细描述
I.3 Primary Objectives :
To determine the MTD of escalating doses of clofarabine starting from 20 mg/m2/day to 40 mg/m2/day from day 1 to day 5, as a replacement of cytarabine as part of a combination of etoposide, asparaginase, mitoxantrone and dexamethasone (VANDA regimen).
I.4 Secondary Objectives :
- To determine the safety and tolerability of clofarabine when used in combination with etoposide, asparaginase, mitoxantrone and dexamethasone (VANDA regimen) and determine the duration, seriousness, and relationship of adverse events that occur during the treatment and follow-up periods ; we search DLT
- To determine the Overall Response rate (OR) (Complete Remission + Complete Remission without platelet's normalization) of clofarabine plus etoposide ,asparaginase, mitoxantrone and dexamethasone (VANDA regimen) in pediatric patients with refractory or relapsed ALL at the established clofarabine RP2D.
- To document the rate of Partial Response[s] in the study population
- To document time-to-event parameters, including duration of remission, Event Free Survival (EFS), 4-month EFS, and overall survival (OS).
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 1 Year 至 23 Years（Child, Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •1 to 21 years old at the date of acute lymphoblastic leukemia initial diagnosis
- •Very early medullary first relapse occurring during the first 18th months after complete remission OR patients with second relapse OR a relapse occurring 6 months or more after myeloablative stem cell transplantation will be eligible.
- •Have a Karnofsky Performance Status (KPS) of ≥70 for patients >10 years of age or a Lansky Performance Status (LPS) of ≥60 for patients ≤10 years of age.
- •No concomitant malignant disease.
- •No active uncontrolled infection.
- •Have adequate renal and hepatic functions
- •absence of concomitant severe cardiovascular disease, i.e. congestive heart failure
- •Female patients of childbearing potential must have a negative serum pregnancy test within 2 weeks prior to enrollment.
- •Male and female patients must use an effective contraceptive method during the study and for a minimum of 6 months after study treatment.
排除标准
- •Current concomitant chemotherapy, radiation therapy, or immunotherapy other than as specified in the protocol.
- •Use of any investigational agent within 30 days.
- •Known hypersensitivity to clofarabine or excipients.
- •Known hypersensitivity to mitoxantrone, etoposide or excipients.
- •Allergy to both E Coli-Asparaginase and Erwinia Asparaginase
- •Prior transplant less than 6 months ago.
- •Trisomy 21
- •Have any other severe concurrent disease, or have a history of serious organ dysfunction or disease involving the heart, kidney, liver, or other organ system that may place the patient at undue risk to undergo treatment.
- •Patients with a systemic fungal, bacterial, viral, or other infection not controlled (defined as exhibiting ongoing signs/symptoms related to the infection and without improvement, despite appropriate antibiotics or other treatment).
- •Pregnant or lactating patients.
- •Any significant concurrent disease, illness, or psychiatric disorder that would compromise patient safety or compliance, interfere with consent, study participation, follow up, or interpretation of study results.
结局指标
主要结局
maximum tolerated dose of clofarabine in combination with etoposide, asparaginase, mitoxantrone and dexamethasone
时间窗: within the 40 days after the chemotherapy
次要结局
- efficacy of clofarabine used in combination with etoposide, asparaginase, mitoxantrone and dexamethasone(40 days after the chemotherapy)
- Event free survival(4 months)
研究者
研究点 (4)
Loading locations...
相似试验
终止
1 期
Phase I Dose-Escalation Trial of Clofarabine Followed by Escalating Doses of Fractionated Cyclophosphamide in Children With Relapsed or Refractory Acute LeukemiasAcute Promyelocytic LeukemiaMyeloproliferative DisordersAcute Lymphocytic LeukemiaAcute Myeloid LeukemiaMyelodysplastic SyndromeAcute LeukemiaChronic Myelogenous LeukemiaChronic Myelomonocytic LeukemiaMyelofibrosisJuvenile Myelomonocytic LeukemiaNCT00852709Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins35
已完成
1 期
Clofarabine in High Risk Myelodysplastic Syndrome (MDS)Myelodysplastic SyndromeNCT01063257Groupe Francophone des Myelodysplasies76
已完成
1 期
Phase I Trial of Clofarabine in Combo w/ HD Etoposide & Cyclophosphamide and APBSCT for Pts w/ High-Risk or Refractory NHLNon Hodgkin's LymphomaNCT00477945Indiana University School of Medicine18
撤回
1 期
Oral Clofarabine in Chronic Lymphocytic Leukemia (CLL)Chronic Lymphocytic LeukemiaLeukemiaNCT00800566M.D. Anderson Cancer Center
已完成
1 期
A Phase I Trial of Myeloablative Conditioning w/ Clofarabine and HD Busulfan for Pts w/ Refractory Heme Malignancies Undergoing Allo PBSCTHematologic MalignanciesNCT00477542Indiana University School of Medicine18